DE19822509A1 - Edelfosin zur Behandlung von Hirntumoren - Google Patents
Edelfosin zur Behandlung von HirntumorenInfo
- Publication number
- DE19822509A1 DE19822509A1 DE19822509A DE19822509A DE19822509A1 DE 19822509 A1 DE19822509 A1 DE 19822509A1 DE 19822509 A DE19822509 A DE 19822509A DE 19822509 A DE19822509 A DE 19822509A DE 19822509 A1 DE19822509 A1 DE 19822509A1
- Authority
- DE
- Germany
- Prior art keywords
- treatment
- therapy
- edelfosin
- tumor
- brain tumors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000003174 Brain Neoplasms Diseases 0.000 title claims abstract description 30
- 238000011282 treatment Methods 0.000 title claims abstract description 30
- 239000003814 drug Substances 0.000 claims abstract description 21
- HLMJLPCUSSWQHU-SSYAZFEXSA-N CCCCCCCCCCCCCCCCCCC(C[N+](C)(C)C)OP([O-])(OC[C@@H](CO)OC)=O Chemical compound CCCCCCCCCCCCCCCCCCC(C[N+](C)(C)C)OP([O-])(OC[C@@H](CO)OC)=O HLMJLPCUSSWQHU-SSYAZFEXSA-N 0.000 claims abstract 2
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 6
- MHFRGQHAERHWKZ-HHHXNRCGSA-N (R)-edelfosine Chemical compound CCCCCCCCCCCCCCCCCCOC[C@@H](OC)COP([O-])(=O)OCC[N+](C)(C)C MHFRGQHAERHWKZ-HHHXNRCGSA-N 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 235000013336 milk Nutrition 0.000 claims description 3
- 239000008267 milk Substances 0.000 claims description 3
- 210000004080 milk Anatomy 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 239000012876 carrier material Substances 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 description 42
- 206010028980 Neoplasm Diseases 0.000 description 41
- 229940079593 drug Drugs 0.000 description 18
- 230000004083 survival effect Effects 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 17
- 238000002512 chemotherapy Methods 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 230000005855 radiation Effects 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 11
- 201000011510 cancer Diseases 0.000 description 10
- 239000000824 cytostatic agent Substances 0.000 description 8
- 230000001085 cytostatic effect Effects 0.000 description 8
- 238000001356 surgical procedure Methods 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 206010018338 Glioma Diseases 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 230000003285 pharmacodynamic effect Effects 0.000 description 7
- 229960005536 Alkyl-lysophospholipid Drugs 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 230000000857 drug effect Effects 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 5
- 208000005017 glioblastoma Diseases 0.000 description 5
- 230000008901 benefit Effects 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000000750 progressive effect Effects 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000006641 stabilisation Effects 0.000 description 4
- 238000011105 stabilization Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 206010003571 Astrocytoma Diseases 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 206010028817 Nausea and vomiting symptoms Diseases 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000008499 blood brain barrier function Effects 0.000 description 3
- 210000001218 blood-brain barrier Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000002591 computed tomography Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 206010059282 Metastases to central nervous system Diseases 0.000 description 2
- 206010060860 Neurological symptom Diseases 0.000 description 2
- 208000019155 Radiation injury Diseases 0.000 description 2
- 208000032140 Sleepiness Diseases 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- 229960005243 carmustine Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000006882 induction of apoptosis Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 230000003505 mutagenic effect Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- MHFRGQHAERHWKZ-UHFFFAOYSA-N 1-octadecyl-2-methylglycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCCOCC(OC)COP([O-])(=O)OCC[N+](C)(C)C MHFRGQHAERHWKZ-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010006417 Bronchial carcinoma Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 235000014066 European mistletoe Nutrition 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028400 Mutagenic effect Diseases 0.000 description 1
- ZRKWMRDKSOPRRS-UHFFFAOYSA-N N-Methyl-N-nitrosourea Chemical compound O=NN(C)C(N)=O ZRKWMRDKSOPRRS-UHFFFAOYSA-N 0.000 description 1
- BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 206010061924 Pulmonary toxicity Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 235000012300 Rhipsalis cassutha Nutrition 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- 241000221012 Viscum Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 206010002224 anaplastic astrocytoma Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000011340 continuous therapy Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 231100000351 embryotoxic Toxicity 0.000 description 1
- 230000001779 embryotoxic effect Effects 0.000 description 1
- 210000000219 ependymocyte Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 239000002389 essential drug Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000002575 gastroscopy Methods 0.000 description 1
- 231100000722 genetic damage Toxicity 0.000 description 1
- 208000002409 gliosarcoma Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 235000015141 kefir Nutrition 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000009189 magnetic resonance therapy Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 235000013384 milk substitute Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000009126 molecular therapy Methods 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 231100000243 mutagenic effect Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000003557 neuropsychological effect Effects 0.000 description 1
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical class NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 1
- 206010073131 oligoastrocytoma Diseases 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940000673 orphan drug Drugs 0.000 description 1
- 239000002859 orphan drug Substances 0.000 description 1
- 238000009116 palliative therapy Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 231100000374 pneumotoxicity Toxicity 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 208000030266 primary brain neoplasm Diseases 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000007047 pulmonary toxicity Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 231100000378 teratogenic Toxicity 0.000 description 1
- 230000003390 teratogenic effect Effects 0.000 description 1
- 231100000155 toxicity by organ Toxicity 0.000 description 1
- 230000007675 toxicity by organ Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19822509A DE19822509A1 (de) | 1998-05-19 | 1998-05-19 | Edelfosin zur Behandlung von Hirntumoren |
| EP99952070A EP1079838B1 (de) | 1998-05-19 | 1999-05-11 | Edelfosin zur behandlung von hirntumoren |
| AT99952070T ATE223721T1 (de) | 1998-05-19 | 1999-05-11 | Edelfosin zur behandlung von hirntumoren |
| JP2000549264A JP2002515439A (ja) | 1998-05-19 | 1999-05-11 | 脳腫瘍の治療のためのエーデルホシン |
| US09/700,903 US6514519B1 (en) | 1998-05-19 | 1999-05-11 | Edelfosin for the treatment of brain tumors |
| PCT/EP1999/003241 WO1999059599A1 (de) | 1998-05-19 | 1999-05-11 | Edelfosin zur behandlung von hirntumoren |
| DE59902666T DE59902666D1 (de) | 1998-05-19 | 1999-05-11 | Edelfosin zur behandlung von hirntumoren |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19822509A DE19822509A1 (de) | 1998-05-19 | 1998-05-19 | Edelfosin zur Behandlung von Hirntumoren |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE19822509A1 true DE19822509A1 (de) | 1999-11-25 |
Family
ID=7868323
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19822509A Withdrawn DE19822509A1 (de) | 1998-05-19 | 1998-05-19 | Edelfosin zur Behandlung von Hirntumoren |
| DE59902666T Expired - Lifetime DE59902666D1 (de) | 1998-05-19 | 1999-05-11 | Edelfosin zur behandlung von hirntumoren |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE59902666T Expired - Lifetime DE59902666D1 (de) | 1998-05-19 | 1999-05-11 | Edelfosin zur behandlung von hirntumoren |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US6514519B1 (https=) |
| EP (1) | EP1079838B1 (https=) |
| JP (1) | JP2002515439A (https=) |
| AT (1) | ATE223721T1 (https=) |
| DE (2) | DE19822509A1 (https=) |
| WO (1) | WO1999059599A1 (https=) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007124733A3 (de) * | 2006-04-28 | 2008-01-24 | Dieter Mueller-Enoch | Verwendung von substituierten glycerinderivaten zur herstellung einer pharmazeutischen zubereitung |
| WO2008055996A1 (en) * | 2006-11-10 | 2008-05-15 | Alphaptose Gmbh | Oral dosage form comprising tri-substituted glycerol compounds |
| WO2008055997A1 (en) * | 2006-11-10 | 2008-05-15 | Alphaptose Gmbh | Use of tri-substituted glycerol compounds for the treatment of radiation injuries |
| WO2008074573A1 (en) * | 2006-12-20 | 2008-06-26 | Alphaptose Gmbh | Topical dosage form comprising tri-substituted glycerol compounds |
| WO2008055995A3 (en) * | 2006-11-10 | 2008-10-16 | Alphaptose Gmbh | Methods and compositions for detecting receptor ligand mimetics |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002531534A (ja) * | 1998-12-04 | 2002-09-24 | マックス−デルブルック−セントラム フュール モレクラーレ メディツィン | タモキシフェン含有リポソーム系腫瘍治療剤 |
| US7041302B2 (en) | 2001-01-09 | 2006-05-09 | Biother Corporation | Therapeutic modulation of the tumor inflammatory response |
| JP2008539721A (ja) * | 2005-05-02 | 2008-11-20 | ザ トラスティース オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク | アルツハイマー病の治療のためのホスホイノシチドモジュレーション |
| CA2673040C (en) | 2006-12-20 | 2016-02-02 | Universitaetsklinikum Hamburg-Eppendorf | Use of tri-substituted glycerol compounds for the treatment of hematological malignancies |
| AU2008254328A1 (en) | 2007-05-18 | 2008-11-27 | The Johns Hopkins University | A treatment simulator for brain diseases and method of use thereof |
| RU2382765C1 (ru) * | 2008-10-24 | 2010-02-27 | Государственное образовательное учреждение высшего профессионального образования "Московская государственная академия тонкой химической технологии имени М.В. Ломоносова" | Rac-N,N-ДИМЕТИЛ-N-[2-(5-N',N'- ДИМЕТИЛАМИНОНАФТАЛЕН-1-СУЛЬФОНИЛОКСИ)ЭТИЛ]-N- {4-[(2-МЕТОКСИ-3-ОКТАДЕЦИЛОКСИ)ПРОП-1-ИЛОКСИКАРБОНИЛ]БУТИЛ} АММОНИЙИОДИД |
| WO2013156630A1 (en) | 2012-04-20 | 2013-10-24 | Alphaptose Gmbh | S-enantiomer of a tri-substituted glycerol compound |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3941009A1 (de) * | 1989-12-12 | 1991-06-13 | Medmark Pharma Gmbh | Eliminierung von aktivierten lymphozyten |
| DE4000084A1 (de) * | 1990-01-03 | 1991-07-04 | Medmark Pharma Gmbh | Intravenoes applizierbare pharmazeutische zubereitung von et18-och(pfeil abwaerts)3(pfeil abwaerts) |
| US5925669A (en) * | 1994-03-22 | 1999-07-20 | Molecular/Structural Bio Technologies, Inc. | Carrier compositions for anti-neoplastic drugs |
| WO1997035588A1 (en) * | 1996-03-27 | 1997-10-02 | Uab Research Foundation | Novel uses of phospholipase c inhibitors |
-
1998
- 1998-05-19 DE DE19822509A patent/DE19822509A1/de not_active Withdrawn
-
1999
- 1999-05-11 US US09/700,903 patent/US6514519B1/en not_active Expired - Fee Related
- 1999-05-11 EP EP99952070A patent/EP1079838B1/de not_active Expired - Lifetime
- 1999-05-11 JP JP2000549264A patent/JP2002515439A/ja active Pending
- 1999-05-11 WO PCT/EP1999/003241 patent/WO1999059599A1/de not_active Ceased
- 1999-05-11 AT AT99952070T patent/ATE223721T1/de not_active IP Right Cessation
- 1999-05-11 DE DE59902666T patent/DE59902666D1/de not_active Expired - Lifetime
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007124733A3 (de) * | 2006-04-28 | 2008-01-24 | Dieter Mueller-Enoch | Verwendung von substituierten glycerinderivaten zur herstellung einer pharmazeutischen zubereitung |
| WO2008055996A1 (en) * | 2006-11-10 | 2008-05-15 | Alphaptose Gmbh | Oral dosage form comprising tri-substituted glycerol compounds |
| WO2008055997A1 (en) * | 2006-11-10 | 2008-05-15 | Alphaptose Gmbh | Use of tri-substituted glycerol compounds for the treatment of radiation injuries |
| WO2008055995A3 (en) * | 2006-11-10 | 2008-10-16 | Alphaptose Gmbh | Methods and compositions for detecting receptor ligand mimetics |
| WO2008074573A1 (en) * | 2006-12-20 | 2008-06-26 | Alphaptose Gmbh | Topical dosage form comprising tri-substituted glycerol compounds |
Also Published As
| Publication number | Publication date |
|---|---|
| ATE223721T1 (de) | 2002-09-15 |
| DE59902666D1 (de) | 2002-10-17 |
| EP1079838B1 (de) | 2002-09-11 |
| WO1999059599A1 (de) | 1999-11-25 |
| EP1079838A1 (de) | 2001-03-07 |
| JP2002515439A (ja) | 2002-05-28 |
| US6514519B1 (en) | 2003-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69736976T2 (de) | Mit Alzheimer Krankheit verknüpften Verfahren zur Diagnose, zur Herstellung von Medikamenten und zum Screenen von Substanzen sowie aus Beta-Amyloid abgeleiteten Peptiden | |
| EP1079838B1 (de) | Edelfosin zur behandlung von hirntumoren | |
| DE60004348T2 (de) | Kombinierte vorbereitungen, die morpholin anthracyclin und platin derivate | |
| Jost et al. | Long‐term results with cisapride in Parkinson's disease | |
| CN113473983B (zh) | 通过施用树脂毒素治疗帕金森病的方法 | |
| EVANS et al. | Early changes in the rat hippocampus following seizures induced by bicuculline or L‐allylglycine: a light and electron microscope study | |
| EP2862572B1 (en) | Prophylactic and/or therapeutic agent for mild cognitive impairment | |
| AU2019203526A1 (en) | GALANTAMINE CLEARANCE OF AMYLOIDß | |
| DE69021415T2 (de) | Mittel zur Behandlung von seniler Demenz, Gedächtnisstörungen und ähnlichen Zuständen. | |
| Schmid-Elsaesser et al. | EEG burst suppression is not necessary for maximum barbiturate protection in transient focal cerebral ischemia in the rat | |
| TARAZI et al. | Spinal cord lesions produced by aortography in dogs | |
| AU2015258814B2 (en) | Clearance of amyloid ss | |
| DE112018004197T5 (de) | Zusammensetzung zur prävention oder behandlung von krebs, beinhaltend triazolpyridin-basiertes derivat als wirkstoff | |
| Peterson et al. | Hydroethidine detection of superoxide production during the lithium–pilocarpine model of status epilepticus | |
| EP1091744A1 (de) | 1-octadecyl-2-methyl-sn-glycero-3-phosphocholin (et180ch3) zur behandlung von humanen mammakarzinomen | |
| AU2011285703B2 (en) | Methods and pharmaceutical compositions for treating adverse or deleterious sequellae of traumatic brain injury | |
| WO2003053445A1 (de) | Verwendung von desoxypeganin zur behandlung der klinischen depression | |
| CA3238640A1 (en) | Method for treating cancer with acylfulvene and radiation | |
| KR101532211B1 (ko) | Ampk 억제기능에 기반한 뇌졸중 치료용 약학적 조성물 및 방법 | |
| DE112006002340T5 (de) | Arzneimittel, verwendbar zur Behandlung von Prostatakrebs | |
| EP0344158B1 (de) | Schmerzpräparat | |
| Monfared et al. | Investigating the Effectiveness of Silymarin in Treatment of Migraine Patients Referred to Medical Centers Affiliated to Arak University of Medical Science | |
| TWI286936B (en) | New use of tetramethylpyrazine in the treatment of brain tumor | |
| Jones | Neurological involvement in the lymphomas and leukemias. Radiotherapy | |
| Harro et al. | Chronic mild stress prevents the development of behavioural changes after noradrenergic denervation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8139 | Disposal/non-payment of the annual fee |